The EPIC-Norfolk Study
A comparative analysis of three widely used lipid management guidelines in the EPIC-Norfolk cohort.
European Journal of Preventive Cardiology 2012 ; 20: 98-106.
Colkesen EB, Jørstad HT, Peters RJ, Boekholdt SM, Tijssen JG, Ferket BS, Wareham NJ, and Khaw KT
DOI : 10.1177/2047487311435456
PubMed ID : 22345678
PMCID : 0
URL : https://pubmed.ncbi.nlm.nih.gov/22345678/
Abstract
To compare the impact of three major guidelines for the prevention of cardiovascular disease (CVD).
21,263 men and women aged 39-79 years from the EPIC (European Prospective Investigation of Cancer) Norfolk cohort were retrospectively classified at baseline by statin therapy recommendations according to the NICE, ESC and ATPIII CVD prevention guidelines. Recommendations based on baseline data were related to 10-year follow-up to calculate number of new CVD events that could be prevented by statins, number-needed-to-treat (NNT) and CVD incidence decrease. Statin therapy was recommended to 34% by the NICE guideline, 29% by ESC and 32% by ATPIII. A total of 263 events could potentially have been prevented by application of the NICE guideline, 219 by ESC and 199 by ATPIII. The NNT with statins over 10 years was 27 with the NICE guideline, 28 with ESC and 34 with ATPIII. Application of the NICE guideline could have decreased CVD incidence by 13%; using ESC guidelines the figure is 11% and with ATPIII it is 10%.
The NICE guideline selected greater percentages of elderly and subjects with prevalent CVD risk factors. It performed best in recommending statins and could have prevented the greatest number of CVD events. With all guidelines, nearly half the subjects who developed a CVD event were not considered eligible for statins at baseline. Less selective prevention strategies need to be explored.
Study : EPIC-Norfolk: The European Prospective Investigation into Cancer Norfolk Cohort